https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

NIH and Partners Launch HIV Vaccine Efficacy Study Img

NIH and Partners Launch HIV Vaccine Efficacy Study

The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection.

HIV Latency: Trapped in Transition, Lurking in Treg Img

HIV Latency: Trapped in Transition, Lurking in Treg

New research supports the theory that HIV latency occurs when HIV infects a CD4 T cell that is in the process of transitioning from an activated state to a resting state.

Four Big Insights Into HIV/AIDS That Provide Hope of Finding a Vaccine Img

Four Big Insights Into HIV/AIDS That Provide Hope of Finding a Vaccine

Although the goals of an HIV vaccine or cure remain elusive, the research being done makes these goals appear increasingly likely.

Antibodies
IDWeek

Ibalizumab Effective Against Drug-Resistant HIV in 48-Week Data

The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017 Img
News

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017

Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...

How Long for Long-Acting Antiretrovirals? A Top HIV Clinical Development of 2017 Img

How Long for Long-Acting Antiretrovirals? A Top HIV Clinical Development of 2017

It has been fascinating to observe the evolution in HIV clinicians' thinking on long-acting injectable antiretrovirals (LA-ART). It was not that long ago that LA-ART was largely dismissed as suiting only a small niche of patients while most were assu...

Locking Down Latent HIV Img

Locking Down Latent HIV

Researchers are flipping the idea of latency reversal on its head. Their approach -- which they have dubbed block and lock -- involves trying to imprison latent HIV in a way that prevents it from ever reactivating.

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial Img
IDWeek

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial

A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.

HIV Remission: The Quest to Turn Lessons From Exceptional Cases Into Solutions Img

HIV Remission: The Quest to Turn Lessons From Exceptional Cases Into Solutions

Researchers are attempting to establish how to make long-term HIV remission possible after finding that HIV can be suppressed naturally in some people for a long time after they have been on a short spell of treatment.

Long-Acting Drugs for HIV Img

Long-Acting Drugs for HIV

An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.